BE2016C014I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2016C014I2 BE2016C014I2 BE2016C014C BE2016C014C BE2016C014I2 BE 2016C014 I2 BE2016C014 I2 BE 2016C014I2 BE 2016C014 C BE2016C014 C BE 2016C014C BE 2016C014 C BE2016C014 C BE 2016C014C BE 2016C014 I2 BE2016C014 I2 BE 2016C014I2
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56234004P | 2004-04-15 | 2004-04-15 | |
US56909604P | 2004-05-07 | 2004-05-07 | |
US59940104P | 2004-08-06 | 2004-08-06 | |
US61000104P | 2004-09-14 | 2004-09-14 | |
US61000204P | 2004-09-14 | 2004-09-14 | |
US61015904P | 2004-09-14 | 2004-09-14 | |
US62057304P | 2004-10-20 | 2004-10-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
BE2016C014I2 true BE2016C014I2 (enEXAMPLES) | 2024-10-09 |
Family
ID=34965899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE2016C014C BE2016C014I2 (enEXAMPLES) | 2004-04-15 | 2016-04-21 |
Country Status (17)
Country | Link |
---|---|
US (9) | US8129346B2 (enEXAMPLES) |
EP (1) | EP1745064B1 (enEXAMPLES) |
JP (3) | JP5616569B2 (enEXAMPLES) |
CN (2) | CN103554222A (enEXAMPLES) |
AT (1) | ATE494298T1 (enEXAMPLES) |
AU (1) | AU2005238445B2 (enEXAMPLES) |
BE (1) | BE2016C014I2 (enEXAMPLES) |
BR (1) | BRPI0509879A (enEXAMPLES) |
CA (1) | CA2562411A1 (enEXAMPLES) |
CY (1) | CY1117244T1 (enEXAMPLES) |
DE (1) | DE602005025750D1 (enEXAMPLES) |
DK (1) | DK1745064T3 (enEXAMPLES) |
IL (3) | IL178400A (enEXAMPLES) |
PL (1) | PL1745064T3 (enEXAMPLES) |
PT (1) | PT1745064E (enEXAMPLES) |
SG (2) | SG152239A1 (enEXAMPLES) |
WO (1) | WO2005105827A2 (enEXAMPLES) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1745064B1 (en) | 2004-04-15 | 2011-01-05 | Proteolix, Inc. | Compounds for proteasome enzyme inhibition |
AU2012203602B2 (en) * | 2004-04-15 | 2015-08-27 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
US8198270B2 (en) * | 2004-04-15 | 2012-06-12 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
US7232818B2 (en) * | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
DK2030981T3 (da) | 2004-05-10 | 2014-10-13 | Onyx Therapeutics Inc | Forbindelser til proteasom-enzymhæmning |
PL2261236T3 (pl) | 2004-12-07 | 2015-12-31 | Onyx Therapeutics Inc | Kompozycja do hamowania proteasomu |
EP1948678B1 (en) | 2005-11-09 | 2013-05-01 | Onyx Therapeutics, Inc. | Compounds for enzyme inhibition |
AU2007261345B2 (en) * | 2006-06-19 | 2012-02-23 | Onyx Therapeutics, Inc. | Peptide epoxyketones for proteasome inhibition |
KR20160086980A (ko) | 2007-10-04 | 2016-07-20 | 오닉스 세라퓨틱스, 인크. | 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성 |
BRPI0919668A2 (pt) * | 2008-10-21 | 2018-05-29 | Onyx Therapeutics, Inc. | terapia de combinação com epóxi-cetonas de peptídeo |
ES2634431T3 (es) * | 2009-03-16 | 2017-09-27 | The Governing Council Of The University Of Toronto | Moléculas de aminoácidos cíclicos y procedimientos de preparación de las mismas |
AR075899A1 (es) | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
GB0914883D0 (en) | 2009-08-26 | 2009-09-30 | Univ Belfast | Compound |
JP5919196B2 (ja) | 2009-11-13 | 2016-05-18 | オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. | 転移抑制のためのペプチドエポキシケトンの使用 |
MA34133B1 (fr) | 2010-03-01 | 2013-04-03 | Onyx Therapeutics Inc | Composes pour inhibiteurs de l'immunoproteasome |
US8697646B2 (en) | 2010-04-07 | 2014-04-15 | Onyx Therapeutics, Inc. | Crystalline peptide epoxyketone immunoproteasome inhibitor |
KR20220088949A (ko) * | 2012-05-08 | 2022-06-28 | 오닉스 세라퓨틱스, 인크. | 펩티드 프로테아좀 억제제 제제화를 위한 사이클로덱스트린 복합체화 방법 |
US20140105921A1 (en) | 2012-07-09 | 2014-04-17 | Onyx Therapeutics, Inc. | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors |
US10076384B2 (en) | 2013-03-08 | 2018-09-18 | Symple Surgical, Inc. | Balloon catheter apparatus with microwave emitter |
PL2968555T3 (pl) | 2013-03-13 | 2020-11-16 | Sanofi | Kompozycje zawierające przeciwciała anty-cd38 i karfilzomib |
US20160166632A1 (en) | 2013-07-19 | 2016-06-16 | Onyx Therapeutics, Inc. | Peptide epoxyketone proteasome inhibitors in combination with pim kinase inhibitors for treatment of cancers |
CN103360348B (zh) * | 2013-07-25 | 2015-06-24 | 苏州鹏旭医药科技有限公司 | 一种Carfilzomib中间体及其制备方法和制备Carfilzomib的方法 |
EP3041856A1 (en) * | 2013-09-06 | 2016-07-13 | Sandoz AG | Synthesis of peptide epoxy ketones |
WO2015032622A1 (en) * | 2013-09-06 | 2015-03-12 | Sandoz Ag | Stereoselective synthesis of diols and triols by mannich reaction and their use in the synthesis of carfilzomib |
CN104710507B (zh) * | 2013-12-11 | 2018-08-14 | 深圳翰宇药业股份有限公司 | 一种卡非佐米的制备方法 |
WO2015121769A1 (en) | 2014-02-13 | 2015-08-20 | Ranbaxy Laboratories Limited | Process for the preparation of methyl n-[(benzyloxy)-carbonyl]-l-leucyl-l-phenylalaninate |
DK3166933T3 (en) | 2014-07-14 | 2018-11-26 | Centrax Int Inc | EPOXYKETONE COMPOUNDS FOR ENZYME INHIBITION |
US10329325B2 (en) | 2014-09-24 | 2019-06-25 | Biophore India Pharmaceuticals Pvt. Ltd | Process for the preparation of (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxo-pentan-2-yl) amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido) pentanamide |
US20160115198A1 (en) | 2014-10-27 | 2016-04-28 | Apicore Us Llc | Methods of making carfilzomib and intermediates thereof |
ES2742196T3 (es) | 2014-12-02 | 2020-02-13 | Fresenius Kabi Oncology Ltd | Un procedimiento para la purificación de carfilzomib |
WO2016108204A1 (en) | 2014-12-31 | 2016-07-07 | Dr. Reddy's Laboratories Limited | Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib |
WO2016116882A2 (en) * | 2015-01-23 | 2016-07-28 | Leiutis Pharmaceuticals Pvt Ltd | Novel compositions of carfilzomib |
US10544189B2 (en) * | 2015-04-22 | 2020-01-28 | Msn Laboratories Private Limited | Process for the preparation of (2S)-N-((S)-1-((S)-4-methyl-1-((R)-2-methyl oxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)-4-methylpentanamide |
WO2016170489A1 (en) | 2015-04-24 | 2016-10-27 | Fresenius Kabi Oncology Ltd. | Pharmaceutical compositions of proteasome inhibitor |
US10364269B2 (en) | 2015-05-21 | 2019-07-30 | Laurus Labs Limited | Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof |
US11046695B2 (en) | 2015-11-11 | 2021-06-29 | Zealand Pharma A/S | Fragment synthesis of substituted cyclic peptides |
WO2018024645A1 (en) | 2016-08-02 | 2018-02-08 | Synthon B.V. | Process for making carfilzomib |
US11078231B2 (en) | 2016-09-14 | 2021-08-03 | Fresenius Kabi Oncology Ltd | Process for purification of carfilzomib intermediate |
JP7035044B2 (ja) | 2016-11-11 | 2022-03-14 | ジーランド ファーマ エー/エス | α4β7インテグリンを標的とする環状ペプチド多量体 |
EP3330260A1 (en) | 2016-12-01 | 2018-06-06 | Enantia, S.L. | Process for the preparation of an intermediate for the synthesis of i.a. carfilzomib |
CN106946981B (zh) * | 2017-03-08 | 2020-08-21 | 南京陵瑞医药科技有限公司 | 一种四肽环氧丙烷衍生物及其制备方法和用途 |
MX2019013362A (es) | 2017-05-10 | 2020-08-17 | Zealand Pharma As | PÉPTIDOS CÍCLICOS HOMODÉTICOS CON LA INTEGRINA A4ß7 COMO DIANA. |
EP3694878A1 (en) | 2017-09-14 | 2020-08-19 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatment for cancer |
CN113185575B (zh) * | 2021-05-11 | 2022-07-12 | 四川大学 | 一种花生抗氧化多肽及其制备方法 |
JP2025516629A (ja) | 2022-05-11 | 2025-05-30 | セルジーン コーポレーション | T細胞療法に関連する方法および使用、ならびにその生成 |
US20250302954A1 (en) | 2022-05-11 | 2025-10-02 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
WO2024097905A1 (en) | 2022-11-02 | 2024-05-10 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4733665C2 (en) * | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
JPH01136498A (ja) | 1987-11-21 | 1989-05-29 | Nec Corp | 状態監視用情報伝送装置 |
US5135919A (en) * | 1988-01-19 | 1992-08-04 | Children's Medical Center Corporation | Method and a pharmaceutical composition for the inhibition of angiogenesis |
US5441944A (en) * | 1989-04-23 | 1995-08-15 | The Trustees Of The University Of Pennsylvania | Substituted cyclodextrin sulfates and their uses as growth modulating agents |
US4990448A (en) | 1989-08-04 | 1991-02-05 | Bristol-Myers Company | Bu-4061T |
US5071957A (en) * | 1989-08-04 | 1991-12-10 | Bristol-Myers Company | Antibiotic BU-4061T |
KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) * | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
IL97428A0 (en) | 1990-03-05 | 1992-06-21 | Cephalon Inc | Chymotrypsin-like proteases and their inhibitors |
US5340736A (en) | 1991-05-13 | 1994-08-23 | The President & Fellows Of Harvard College | ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting |
GB9300048D0 (en) * | 1993-01-04 | 1993-03-03 | Wellcome Found | Endothelin converting enzyme inhibitors |
US5693617A (en) | 1994-03-15 | 1997-12-02 | Proscript, Inc. | Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein |
US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
US6335358B1 (en) | 1995-04-12 | 2002-01-01 | President And Fellows Of Harvard College | Lactacystin analogs |
WO1998010779A1 (en) | 1996-09-13 | 1998-03-19 | New York University | Method for treating parasitic diseases with proteasome inhibitors |
SI0932617T1 (en) | 1996-10-18 | 2002-06-30 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
UA66767C2 (uk) * | 1996-10-18 | 2004-06-15 | Вертекс Фармасьютикалс Інкорпорейтед | Інгібітори серин-протеаз, фармацевтична композиція, спосіб інгібування активності та спосіб лікування або профілактики вірусної інфекції гепатиту с |
JP4269015B2 (ja) | 1996-12-13 | 2009-05-27 | オステオスクリーン アイピー, エルエルシー | 骨の成長を刺激する組成物および方法 |
US5874418A (en) * | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
US6046177A (en) * | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
ATE253941T1 (de) * | 1997-06-13 | 2003-11-15 | Cydex Inc | Zusammensetzung mit erhöhter lagerstabilität enthaltend cyclodextrin und wirkstoffe oder wirkstoff-vorstufen, die in wasserunlösliche komponenten zersetzt werden |
US6099851A (en) * | 1998-06-02 | 2000-08-08 | Weisman; Kenneth M. | Therapeutic uses of leuprolide acetate |
US6902721B1 (en) * | 1998-07-10 | 2005-06-07 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
US6838436B1 (en) * | 1998-07-10 | 2005-01-04 | Osteoscreen Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
US6462019B1 (en) * | 1998-07-10 | 2002-10-08 | Osteoscreen, Inc. | Inhibitors of proteasomal activity and production for stimulating bone growth |
US6204257B1 (en) * | 1998-08-07 | 2001-03-20 | Universtiy Of Kansas | Water soluble prodrugs of hindered alcohols |
WO2000023614A1 (en) * | 1998-10-20 | 2000-04-27 | Millennium Pharmaceuticals, Inc. | Method for monitoring proteasome inhibitor drug action |
US6492333B1 (en) * | 1999-04-09 | 2002-12-10 | Osteoscreen, Inc. | Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors |
US6831099B1 (en) * | 1999-05-12 | 2004-12-14 | Yale University | Enzyme inhibition |
EP1221962A2 (en) * | 1999-10-20 | 2002-07-17 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone and hair growth |
AU2002218133A1 (en) * | 2000-10-12 | 2002-04-22 | Viromics Gmbh | Agents for the treatment of viral infections |
US7524883B2 (en) * | 2002-01-08 | 2009-04-28 | Eisai R&D Management Co., Ltd. | Eponemycin and epoxomicin analogs and uses thereof |
WO2003086283A2 (en) * | 2002-04-09 | 2003-10-23 | Greenville Hospital System | Metastasis modulating activity of highly sulfated oligosaccharides |
US20030224469A1 (en) * | 2002-06-03 | 2003-12-04 | Buchholz Tonia J. | Methods and kits for assays utilizing fluorescence polarization |
US7232818B2 (en) * | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
EP1745064B1 (en) | 2004-04-15 | 2011-01-05 | Proteolix, Inc. | Compounds for proteasome enzyme inhibition |
US8198270B2 (en) * | 2004-04-15 | 2012-06-12 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
US20050256324A1 (en) * | 2004-05-10 | 2005-11-17 | Proteolix, Inc. | Synthesis of amino acid keto-epoxides |
DK2030981T3 (da) | 2004-05-10 | 2014-10-13 | Onyx Therapeutics Inc | Forbindelser til proteasom-enzymhæmning |
US20060088471A1 (en) * | 2004-10-20 | 2006-04-27 | Proteolix, Inc. | Compounds for enzyme inhibition |
PL2261236T3 (pl) * | 2004-12-07 | 2015-12-31 | Onyx Therapeutics Inc | Kompozycja do hamowania proteasomu |
US7589066B2 (en) * | 2005-03-11 | 2009-09-15 | The University Of North Carolina At Chapel Hill | Potent and specific immunoproteasome inhibitors |
EP1948678B1 (en) * | 2005-11-09 | 2013-05-01 | Onyx Therapeutics, Inc. | Compounds for enzyme inhibition |
AR057227A1 (es) | 2005-12-09 | 2007-11-21 | Centocor Inc | Metodo para usar antagonistas de il6 con inhibidores del proteasoma |
DE102006026464A1 (de) * | 2006-06-01 | 2007-12-06 | Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma | Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus |
AU2007261345B2 (en) * | 2006-06-19 | 2012-02-23 | Onyx Therapeutics, Inc. | Peptide epoxyketones for proteasome inhibition |
JP4325683B2 (ja) * | 2007-02-14 | 2009-09-02 | セイコーエプソン株式会社 | 画像表示装置、及び画像表示装置の制御方法 |
WO2008140782A2 (en) | 2007-05-10 | 2008-11-20 | Proteolix, Inc. | Compounds for enzyme inhibition |
KR20160086980A (ko) | 2007-10-04 | 2016-07-20 | 오닉스 세라퓨틱스, 인크. | 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성 |
BRPI0919668A2 (pt) | 2008-10-21 | 2018-05-29 | Onyx Therapeutics, Inc. | terapia de combinação com epóxi-cetonas de peptídeo |
-
2005
- 2005-04-14 EP EP05735686A patent/EP1745064B1/en not_active Expired - Lifetime
- 2005-04-14 DK DK05735686.7T patent/DK1745064T3/da active
- 2005-04-14 BR BRPI0509879-3A patent/BRPI0509879A/pt not_active Application Discontinuation
- 2005-04-14 WO PCT/US2005/012740 patent/WO2005105827A2/en active Application Filing
- 2005-04-14 DE DE602005025750T patent/DE602005025750D1/de not_active Expired - Lifetime
- 2005-04-14 CA CA002562411A patent/CA2562411A1/en not_active Abandoned
- 2005-04-14 CN CN201310512372.8A patent/CN103554222A/zh active Pending
- 2005-04-14 CN CN201110037869XA patent/CN102174076A/zh active Pending
- 2005-04-14 SG SG200902548-7A patent/SG152239A1/en unknown
- 2005-04-14 PT PT05735686T patent/PT1745064E/pt unknown
- 2005-04-14 PL PL05735686T patent/PL1745064T3/pl unknown
- 2005-04-14 AT AT05735686T patent/ATE494298T1/de active
- 2005-04-14 US US11/578,626 patent/US8129346B2/en active Active
- 2005-04-14 JP JP2007508543A patent/JP5616569B2/ja not_active Expired - Lifetime
- 2005-04-14 AU AU2005238445A patent/AU2005238445B2/en not_active Expired
- 2005-04-14 SG SG2012076659A patent/SG185306A1/en unknown
-
2006
- 2006-09-28 IL IL178400A patent/IL178400A/en active IP Right Grant
-
2011
- 2011-02-18 CY CY20111100205T patent/CY1117244T1/el unknown
- 2011-09-12 JP JP2011198810A patent/JP2012041346A/ja active Pending
- 2011-12-22 US US13/334,466 patent/US8207126B2/en not_active Expired - Lifetime
- 2011-12-22 US US13/334,263 patent/US8207124B2/en not_active Expired - Lifetime
- 2011-12-22 US US13/334,372 patent/US8324174B2/en not_active Expired - Lifetime
- 2011-12-22 US US13/334,544 patent/US8207127B2/en not_active Expired - Lifetime
- 2011-12-22 US US13/334,288 patent/US8207125B2/en not_active Expired - Lifetime
- 2011-12-22 US US13/334,469 patent/US8207297B2/en not_active Expired - Lifetime
- 2011-12-26 IL IL217211A patent/IL217211A0/en unknown
- 2011-12-26 IL IL217210A patent/IL217210A0/en unknown
-
2012
- 2012-03-02 US US13/411,044 patent/US20120277146A1/en not_active Abandoned
-
2013
- 2013-03-12 US US13/797,740 patent/US20130324459A1/en not_active Abandoned
- 2013-08-05 JP JP2013162017A patent/JP2014012676A/ja active Pending
-
2016
- 2016-04-21 BE BE2016C014C patent/BE2016C014I2/fr unknown